Introduce national policy on admissions to hospitals in two weeks
The Supreme Court, in an order released late on Sunday, directed the Centre to ensure that the deficit of oxygen to treat COVID-19 patients in the national capital should be rectified on or before the midnight of May 3.
A Special Bench led by Justice D.Y. Chandrachud ordered the Centre to act “in collaboration” with States to “prepare a buffer stock of oxygen for emergency purposes and decentralise the location of the emergency stocks”.
“The emergency stocks shall be created within the next four days and is to be replenished on a day-to-day basis, in addition to the existing allocation of oxygen supply to the States,” ordered the Supreme Court in a 64-page order dated April 30, but published on May 2.
Antiviral drug Clevira repurposed for treatment of mild to moderate COVID-19 cases
Photo: Pexels
Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate COVID-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday.
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days. The drug has also proved to be safe on liver and kidney parameters, it said. Clevira, an antiviral formulation, has received regulatory approval as a supportive treatment for mild to moderate COVID-19 cases, the Chennai-based pharmaceutical company said.